Loading…
Korean biotech specializing in antibody-drug-conjugate (ADC) linker technology, licensed to global pharma partners for cancer drugs.
Korean biotech specializing in antibody-drug-conjugate (ADC) linker technology, licensed to global pharma partners for cancer drugs.
Earns upfront and milestone payments when pharma partners license its drug candidates or linker technology, rather than from product sales, so income arrives in lumps and depends on partners advancing programmes. A royalty stream would only follow approvals.
Moat: narrow (IP / patents). Patented, versatile ADC linker platform licensed to multiple global pharma companies.
Headquarters: Daejeon, South Korea · Founded: 2006 · Employees: 180
Size LigaChem Biosciences (141080.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.59B, the 159th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩58,400 on 6 Nov 2026.
Performance Over six months the shares fell 68.2%, against -4.2% for the median peer and -24.5% for the South Korea market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue fell 33.4% over the last twelve months (peer median +4.1%); the operating margin is -208.4% (peer median 11.0%).
Valuation It trades at 18.4× enterprise value to sales against a peer median of 3.7× (3rd most expensive of 20).
Capital Return on invested capital runs 153.4 points below its cost of capital (5.8% WACC).
Next results Next results expected around 18 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩98.8B | ₩142B | ₩126B | ₩34.1B | ₩33.4B |
| Revenue growth | — | +12% | +269% | +2% | — |
| Gross profit | ₩82.2B | ₩122B | ₩107B | ₩15.6B | ₩15.8B |
| EBITDA | -₩199B | -₩100B | -₩16.0B | -₩76.9B | -₩50.9B |
| Net income | -₩179B | -₩74.3B | ₩7.80B | -₩73.7B | -₩45.1B |
| Free cash flow | -₩195B | -₩128B | ₩75.8B | -₩63.6B | -₩11.3B |
| Capital expenditure | ₩5.70B | ₩6.04B | ₩5.70B | ₩2.20B | ₩4.77B |
| Total debt | ₩2.59B | ₩2.75B | ₩820M | ₩12.6B | ₩12.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| LigaChem Biosciences 141080.KS | $1.59B | -68% | -33% | -208% | 18.4× | n/a |
| ABL Bio 298380.KS | $1.49B | -73% | -64% | -251% | 55.7× | n/a |
| Aimed Bio 0009K0.KS | $875M | -61% | +223% | 36% | 16.4× | 13.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 141080.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -27.4% | +4.8% | 2nd lowest of 21 |
| 6-month return | -68.2% | -4.2% | 2nd lowest of 20 |
| Distance from 52-week high | -74.0% | -19.8% | 2nd lowest of 21 |
| Revenue growth (TTM) | -33.4% | +4.1% | 3rd lowest of 20 |
| Operating margin | -208.4% | 11.0% | 3rd lowest of 20 |
| EV / Sales | 18.4× | 3.7× | 3rd most expensive of 20 |
| ROIC minus cost of capital | -153.4 pp | +1.4 pp | lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | 18.4× | n/a | n/a |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 1.7× | n/a | n/a |
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 3.4× | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 9.6× | 37.6% | +16.6% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | 3.7× | -4.1% | +0.2% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.56B | -5% | +4% | 9% | 1.5× | -5.8% | +1.9% |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 15.3× | 39.6% | +359.6% |
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 3.3× | 29.6% | +29.4% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 2.2× | -4.5% | +6.8% |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.55B | +53% | -6% | -19% | 13.6× | 49.9% | -13.2% |
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | 164.1× | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 15.1× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | 3.3× | n/a | n/a |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 2.2× | -15.1% | +13.5% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.67B | -14% | -13% | 6% | 1.2× | -6.0% | -5.6% |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.67B | +1% | -4% | 15% | 4.7× | 6.7% | -4.3% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| NATCO Pharma NATCOPHARM.NS | India | $1.68B | -30% | -21% | 25% | 4.5× | 15.3% | +19.0% |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 2.3× | -8.5% | +4.6% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.69B | -25% | +31% | 10% | 6.5× | 49.3% | +23.0% |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | 55.7× | n/a | n/a |